23andMe reports sales decline day after announcing plans to cut 40% of workforce
23andMe on Tuesday reported declining revenue in its most recent quarter, a day after the company said it will cut 40% of its workforce and shutter its therapeutics business as part of a business restructuring plan.The genetics company reported 50 million in the same period last year. 23andMe's net loss narrowed to 2.32 per share, from 3.17 per share, a year ago.The embattled genetic testing provider ...